Monday, July 12, 2010

Global scenario of microbes, infections, antibiotics and resistance - By Dr. A.J. Tamhankar

Living Caulobacter runaway from dying Caulobacter bacteria.-Exposure to the extracellular DNA (eDNA) released by dying neighboring bacteria stops the sticky holdfasts of living Caulobacter from adhering to surfaces, preventing cells from joining bacterial biofilms. Less sticky cells are more likely to escape established colonies, out to where conditions may be better.
Abbott has received clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.
A commonly used bone marrow stem cell may be able to help treat sepsis, a deadly condition that can occur when an infection spreads throughout the body.
Scientists studying MRSA have identified one of the components responsible for making it so deadly.
Bees could have a key role to play in urgently-needed new treatments to fight virulent MRSA,. A substance known as beeglue or propolis, originating from beehives in the Pacific region, is active against MRSA, which causes potentially fatal infections, particularly in hospital patients.
American Veterinary Medical Association (AVMA) and FDA committed to working together to address antimicrobial resistance concerns in USA.
A modest behavioral intervention program averaging just 35 minutes can measurably reduce the incidence of HIV and sexually transmitted infections (STIs) among female sex workers.
Gen-Probe has announced that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.
Ecolab Launches First EPA-Approved, Ready-to-Use Hard Surface Disinfectant Effective Against Clostridium Difficile
New antibiotics: from honey bees called defensin-1, which could one day be used to treat burns and skin infections and to develop new drugs that could combat antibiotic-resistant infections.
Washington State University and the Gates Foundation form new School for Global Animal Health. for investigating emerging disease. From Avian influenza, to West Nile virus.
ABR Workshop in Nairobi, Kenya and A Curriculum for Community Action on AMR
CDC has published guidelines to address gram-negative bacteria
Fighting Hospital Infections
Modified CO2 processing may render microbes ineffective and extend shelf life of foods
Eating chicken or steak in USA means consuming pharmaceuticals not required by body

Monday, July 5, 2010

Global scenario of microbes, infections, antibiotics and resistance - By Dr. A.J. Tamhankar

-APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam®, which is marketed by Bristol-Myers Squibb.

-Sampling of pigeons captured on the streets of Madrid has revealed that Chlamydophila psittaci and Campylobacter jejuni were highly prevalent in the bird population, , both of which cause illness in humans-e.g.Diorrhea.

-Scientists have completed the most comprehensive comparative analysis to date of bacterial communities inhabiting the human nose and throat, which could provide new insights into why some individuals become colonized with pathogens while others do not. They released their findings in mBio™ the online open-access journal published by the American Society for Microbiology.

-shift in the balance between the "good" bacteria and the "bad" bacteria that populate our gut could be a harbinger of colon cancer.

-Discovery Of the mechanisms by which pathogenic bacterial populations control the way they spread over the surface of the organs they infect and stop when they detect the presence of an antibiotic, Could Help To Design New Strategies To Increase Their Sensitivity To Antibiotics.

-Hospira Receives FDA Approval For Meropenem For Injection, USP (I.V.)

-New, high-powered genomic analytical techniques have established that as many as 1,000 different single-celled species coexist in relative harmony in every healthy human gut.

-United States (U.S.) CDC has issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB). In these landmark guidelines, CDC advises that Interferon Gamma Release Assay (IGRA) blood tests are now preferred over the 100+-year-old tuberculin skin test (TST) for diagnosing TB infection in certain populations

-Survival Rate Up To 100% For Late Stage Treatment Of Anthrax Infections

-A new study indicates different delivery methods of newborn babies has a big effect on the types of microbial communities they harbor

-In a bid to reduce levels of the sexually transmitted infection (STI) chlamydia among young people in London, sexual health charity Terrence Higgins Trust will be inviting young people attending this year's Pride London to take a free chlamydia test during their day out.
-FDA seeks less use of antibiotics in animals to keep them effective for humans (The Washington post)
-News from Europe-A cross-border project including MRSA surveillance and prophylaxis is launched in the European Region of Maas-Rhein, a region including parts of Germany, Belgium and the Netherlands; Norway –New routines for how to report a patient with previously diagnosed MRSA, when he/she is again found positive suggested. Denmark- Decision for stopping the use of cephalosporins in pig farming and doctors demand tougher rules for veterinary AB use; the head of doctors’ union points out that in Denmark 130 tons of ABs are used annually for animals, while only 48 tons for humans. ; Comparison of the sales of veterinary antibacterial agents between 10 European countries

Saturday, July 3, 2010

Global scenario of microbes, infections, antibiotics and resistance - By Dr. A.J. Tamhankar

-New antibiotics-AntibaBoldcterial NXL103 (flopristin/linopristin) starts Phase II clinical trial--- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
- Eschar With Cellulitis as a Clinical Predictor in Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Skin Abscess -A central black eschar with cellulitis has good specificity and high positive predictive value in diagnosing CA-MRSA infection. (The Journal of Emergency Medicine, May 2010)
-'Hidden' tuberculosis raises drug-resistance fears ;New study doubles known rate of infection at a South African hospital.
-MRSA in Patients With Cystic Fibrosis Linked to Shorter Survival Time (CME)
-Extensive Drug Resistance found in Malaria and Tuberculosis
-Tackling antimicrobial resistance- WHO Patient Safety is working towards finding solutions how best to support ongoing international activities to address AMR. Activities are also ongoing to finalize an AMR work plan document during the first half of 2010.
-Bacterial Burden and Wound Outcomes as Influenced by Negative Pressure Wound Therapy
-Vancomycin Dosing: Guidance for Clinicians
-Infection Control Practices in Ambulatory Surgical Centers
-Contraceptive Use to stop infections: New Clinical Guidance From the CDC

Read The ``TRUE LIFE STORY``of a family infected with MRSA